Troponin elevation in heart failure

Prevalence, mechanisms, and clinical implications

Robb D. Kociol, Peter Pang, Mihai Gheorghiade, Gregg C. Fonarow, Christopher M. O'Connor, G. Michael Felker

Research output: Contribution to journalArticle

256 Citations (Scopus)

Abstract

Circulating biomarkers have become increasingly important in diagnosing and risk stratifying patients with heart failure (HF). While the natriuretic peptides have received much focus, there is increasing interest in the role of circulating cardiac troponin (cTn) in detecting myocardial injury (often subclinical) in those with HF. Accumulating evidence suggests that patients with chronic and acute HF may have measurable levels of circulating cTn, whose detection and magnitude may have prognostic implications. Furthermore, as new, more sensitive cTn assays are being developed, larger numbers of HF patients are found to have detectable cTn with a persistent relationship between magnitude and outcome. This knowledge improves our ability to understand the mechanism of worsening HF, improve risk stratification, and detect potential injury related to new therapeutics in HF. As investigators begin to understand the relationship of detectable cTn to HF outcomes, as well as temporal changes in its magnitude, and its relationship to other circulating biomarkers, more insight may be gained into the progressive nature of cardiac dysfunction and the transition from chronic compensated to acute decompensated HF. Ultimately, this information might allow physicians to guide therapy, choose appropriate therapeutics, and improve HF outcomes.

Original languageEnglish (US)
Pages (from-to)1071-1078
Number of pages8
JournalJournal of the American College of Cardiology
Volume56
Issue number14
DOIs
StatePublished - Sep 28 2010
Externally publishedYes

Fingerprint

Troponin
Heart Failure
Biomarkers
Natriuretic Peptides
Wounds and Injuries
Therapeutics
Research Personnel
Physicians

Keywords

  • biomarkers
  • heart failure
  • outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Troponin elevation in heart failure : Prevalence, mechanisms, and clinical implications. / Kociol, Robb D.; Pang, Peter; Gheorghiade, Mihai; Fonarow, Gregg C.; O'Connor, Christopher M.; Felker, G. Michael.

In: Journal of the American College of Cardiology, Vol. 56, No. 14, 28.09.2010, p. 1071-1078.

Research output: Contribution to journalArticle

Kociol, Robb D. ; Pang, Peter ; Gheorghiade, Mihai ; Fonarow, Gregg C. ; O'Connor, Christopher M. ; Felker, G. Michael. / Troponin elevation in heart failure : Prevalence, mechanisms, and clinical implications. In: Journal of the American College of Cardiology. 2010 ; Vol. 56, No. 14. pp. 1071-1078.
@article{65312fd970754eb3b9d7393586fbb549,
title = "Troponin elevation in heart failure: Prevalence, mechanisms, and clinical implications",
abstract = "Circulating biomarkers have become increasingly important in diagnosing and risk stratifying patients with heart failure (HF). While the natriuretic peptides have received much focus, there is increasing interest in the role of circulating cardiac troponin (cTn) in detecting myocardial injury (often subclinical) in those with HF. Accumulating evidence suggests that patients with chronic and acute HF may have measurable levels of circulating cTn, whose detection and magnitude may have prognostic implications. Furthermore, as new, more sensitive cTn assays are being developed, larger numbers of HF patients are found to have detectable cTn with a persistent relationship between magnitude and outcome. This knowledge improves our ability to understand the mechanism of worsening HF, improve risk stratification, and detect potential injury related to new therapeutics in HF. As investigators begin to understand the relationship of detectable cTn to HF outcomes, as well as temporal changes in its magnitude, and its relationship to other circulating biomarkers, more insight may be gained into the progressive nature of cardiac dysfunction and the transition from chronic compensated to acute decompensated HF. Ultimately, this information might allow physicians to guide therapy, choose appropriate therapeutics, and improve HF outcomes.",
keywords = "biomarkers, heart failure, outcomes",
author = "Kociol, {Robb D.} and Peter Pang and Mihai Gheorghiade and Fonarow, {Gregg C.} and O'Connor, {Christopher M.} and Felker, {G. Michael}",
year = "2010",
month = "9",
day = "28",
doi = "10.1016/j.jacc.2010.06.016",
language = "English (US)",
volume = "56",
pages = "1071--1078",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "14",

}

TY - JOUR

T1 - Troponin elevation in heart failure

T2 - Prevalence, mechanisms, and clinical implications

AU - Kociol, Robb D.

AU - Pang, Peter

AU - Gheorghiade, Mihai

AU - Fonarow, Gregg C.

AU - O'Connor, Christopher M.

AU - Felker, G. Michael

PY - 2010/9/28

Y1 - 2010/9/28

N2 - Circulating biomarkers have become increasingly important in diagnosing and risk stratifying patients with heart failure (HF). While the natriuretic peptides have received much focus, there is increasing interest in the role of circulating cardiac troponin (cTn) in detecting myocardial injury (often subclinical) in those with HF. Accumulating evidence suggests that patients with chronic and acute HF may have measurable levels of circulating cTn, whose detection and magnitude may have prognostic implications. Furthermore, as new, more sensitive cTn assays are being developed, larger numbers of HF patients are found to have detectable cTn with a persistent relationship between magnitude and outcome. This knowledge improves our ability to understand the mechanism of worsening HF, improve risk stratification, and detect potential injury related to new therapeutics in HF. As investigators begin to understand the relationship of detectable cTn to HF outcomes, as well as temporal changes in its magnitude, and its relationship to other circulating biomarkers, more insight may be gained into the progressive nature of cardiac dysfunction and the transition from chronic compensated to acute decompensated HF. Ultimately, this information might allow physicians to guide therapy, choose appropriate therapeutics, and improve HF outcomes.

AB - Circulating biomarkers have become increasingly important in diagnosing and risk stratifying patients with heart failure (HF). While the natriuretic peptides have received much focus, there is increasing interest in the role of circulating cardiac troponin (cTn) in detecting myocardial injury (often subclinical) in those with HF. Accumulating evidence suggests that patients with chronic and acute HF may have measurable levels of circulating cTn, whose detection and magnitude may have prognostic implications. Furthermore, as new, more sensitive cTn assays are being developed, larger numbers of HF patients are found to have detectable cTn with a persistent relationship between magnitude and outcome. This knowledge improves our ability to understand the mechanism of worsening HF, improve risk stratification, and detect potential injury related to new therapeutics in HF. As investigators begin to understand the relationship of detectable cTn to HF outcomes, as well as temporal changes in its magnitude, and its relationship to other circulating biomarkers, more insight may be gained into the progressive nature of cardiac dysfunction and the transition from chronic compensated to acute decompensated HF. Ultimately, this information might allow physicians to guide therapy, choose appropriate therapeutics, and improve HF outcomes.

KW - biomarkers

KW - heart failure

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=77957204899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957204899&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2010.06.016

DO - 10.1016/j.jacc.2010.06.016

M3 - Article

VL - 56

SP - 1071

EP - 1078

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 14

ER -